Cargando…
Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants
Atrial fibrillation (AF) is an important cause of preventable, disabling stroke and is increasingly prevalent with advancing age. As life expectancies increase around the world, AF-related stroke is a growing global public health concern. Most AF patients are elderly (≥75 years old) and increasing a...
Autores principales: | Ng, Kuan H., Hart, Robert G., Eikelboom, John W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107426/ https://www.ncbi.nlm.nih.gov/pubmed/25135392 http://dx.doi.org/10.1007/s40119-013-0019-y |
Ejemplares similares
-
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017) -
Prevalence of oral anticoagulation in atrial fibrillation
por: Bartholomay, Eduardo, et al.
Publicado: (2014) -
Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014) -
Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
por: Samoš, Matej, et al.
Publicado: (2022) -
Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)